Literature DB >> 6113864

Hypotensive and sedative effects of alpha-adrenoceptor agonists: relationship to alpha 1- and alpha 2-adrenoceptor potency.

D P Clough, R Hatton.   

Abstract

1 The purpose of this study was to investigate whether the separation between the hypotensive and sedative effects of a new series of centrally acting antihypertensive drugs was due to differences between the relative pre-junctional (alpha(2)) and post-junctional (alpha(1)) adrenoceptor agonist properties of the compounds.2 In anaesthetized rats the intravenous doses of clonidine, ICI 101187, ICI 106270, ICI 109683 and ICI 110802 required to lower blood pressure (BP) by 20 mm Hg were 1.2, 5.1, 5.5, 3.3 and 5.4 mug/kg respectively.3 In a test for sedation, ICI 101187 had at least 10 times less sedative effect than clonidine, ICI 106270 and ICI 109683 had at least 30 times less sedative effect than clonidine while ICI 110802 was not active. In a locomotor activity test the intravenous dose of clonidine required to reduce activity by 50% was 15.3 mug/kg, for ICI 101187 it was 194, for ICI 106270 it was 238 and for 110802 it was 313 mug/kg.4 In the pithed rat the ED(50)s of clonidine, ICI 101187, ICI 106270, ICI 109683 and ICI 110802 as alpha(2)-agonists were 19.4, 9.3, 63.2, 43.0 and 78.5 mug/kg respectively. The alpha(1)-adrenoceptor potencies were quite similar for the five drugs and varied between 3.2 mug/kg for ICI 110802 and 8.7 mu/kg for ICI 106720. Potency as alpha(2)-adrenoceptor agonists was also assessed in the mouse vas deferens. Clonidine and ICI 101187 were similar in potency with IC(50)s of 9.3 x 10(-9)m and 8.9 x 10(-9)m respectively. ICI 106270 and ICI 110802 were much weaker with IC(50)s of 4.9 x 10(-8)m and over 5.7 x 10(-8)m respectively.5 Since all the compounds had similar potencies as alpha(1)-agonists, this could not explain their different sedative effects. The weakest compounds as sedatives were also weakest as alpha(2)-agonists, although ICI 101187 which was as potent as clonidine as an alpha(2)-agonist was still 10 times weaker as a sedative.6 Hypotensive activity appears to be more closely related to alpha(1)- than to alpha(2)-potency.7 Clonidine was more potent as both a sedative and a hypotensive agent than would be predicted from its activity at either the alpha(1)- or the alpha(2)-adrenoceptor.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6113864      PMCID: PMC2071702          DOI: 10.1111/j.1476-5381.1981.tb16793.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  19 in total

1.  Pre- and postsynaptic components in effect of drugs with alpha adrenoceptor affinity.

Authors:  K Starke; T Endo; H D Taube
Journal:  Nature       Date:  1975-04-03       Impact factor: 49.962

Review 2.  Presynaptic regulation of catecholamine release.

Authors:  S Z Langer
Journal:  Biochem Pharmacol       Date:  1974-07-01       Impact factor: 5.858

3.  Sedative effects of alpha-sympathomimetic drugs and their antagonism by adrenergic and cholinergic blocking drugs.

Authors:  B Delbarre; H Schmitt
Journal:  Eur J Pharmacol       Date:  1971       Impact factor: 4.432

4.  Evidence for an alpha-sympathomimetic component in the effects of catapresan on vasomotor centres: antagonism by piperoxane.

Authors:  H Schmitt; S Fenard
Journal:  Eur J Pharmacol       Date:  1971       Impact factor: 4.432

5.  Clonidine-induced inhibition of sympathetic nerve activity: no indication for a central presynaptic or an indirect sympathomimetic mode of action.

Authors:  G Haeusler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

6.  Possible involvement of central adrenaline neurons in vasomotor and respiratory control. Studies with clonidine and its interactions with piperoxane and yohimbine.

Authors:  P Bolme; H Corrodi; K Fuxe; T Hökfelt; P Lidbrink; M Goldstein
Journal:  Eur J Pharmacol       Date:  1974-09       Impact factor: 4.432

7.  Evidence for direct alpha-adrenoceptor stimulation of effector neurons in cardiovascular centers by clonidine.

Authors:  W Kobinger; L Pichler
Journal:  Eur J Pharmacol       Date:  1974-06       Impact factor: 4.432

8.  Sleep produced by clonidine (2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride).

Authors:  R B Holman; E E Shillito; M Vogt
Journal:  Br J Pharmacol       Date:  1971-12       Impact factor: 8.739

9.  The cardiovascular effects of intraventricular clonidine and Bay 1470 in conscious hypertensive cats.

Authors:  L Finch
Journal:  Br J Pharmacol       Date:  1974-11       Impact factor: 8.739

10.  A method of stimulating different segments of the autonomic outflow from the spinal column to various organs in the pithed cat and rat.

Authors:  J S Gillespie; A Maclaren; D Pollock
Journal:  Br J Pharmacol       Date:  1970-10       Impact factor: 8.739

View more
  5 in total

1.  The use of atropine to control heart rate responses during detomidine sedation in horses.

Authors:  C E Short; J L Stauffer; G Goldberg; O Vainio
Journal:  Acta Vet Scand       Date:  1986       Impact factor: 1.695

2.  Typical and atypical neuroleptics are potent antagonists at alpha 1-adrenoceptors of the dorsal lateral geniculate nucleus. An electrophysiological study.

Authors:  J Marwaha; G K Aghajanian
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-10       Impact factor: 3.000

3.  Locomotor activity of rats after stimulation of the nucleus locus coeruleus region or after lesion of the dorsal noradrenergic bundle: effects of clonidine, prazosin and yohimbine.

Authors:  L Velley; E Kempf; B Cardo
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

4.  Ventilatory and cardiovascular effects of BHT 933 in volunteers.

Authors:  B J Pleuvry; J B Redpath
Journal:  Br J Clin Pharmacol       Date:  1982-10       Impact factor: 4.335

5.  Antisecretory activity of the alpha 2-adrenoceptor agonist, xylazine in rat jejunal epithelium.

Authors:  H M Cox; A W Cuthbert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-06       Impact factor: 3.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.